ENROLLEMENT COMPLETED

Article

Maxim pharmaceuticals has completed enrollment for the confirmatory Phase 3 trial of its lead drug candidate Ceplene? (histamine dihydrochloride) in combination with interleukin-2 (IL-2) for the treatment of advanced malignant melanoma patients with liver metastases.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.